Egis to distribute Celltrion's biopharmaceuticals
This article was originally published in Scrip
Executive Summary
Egis has signed an agreement with Celltrion of South Korea to distribute Celltrion's unnamed biosimilars manufactured in accordance with FDA/EMA standards. The agreement is expected to be supplemented in the next few months with other agreements covering the distribution of specific products.